Antitumor Activity and Safety of MK-1308 (Anti-Ctla-4) Plus Pembrolizumab (pembro) in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC): Updated Interim Results from a Phase I Study.
Journal of clinical oncology（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要